Nangibotide LQEEDAGEYGCM-amide

  • Description

  • Application Data

Description

(TREM)-1 antagonist peptide derived from residues 94 to 105 of TREM-like transcript-1 (TLT-1)

See full description

Application Data

Catalogue number crb1001271
Molecular Weight 1342.5
Sequence (one letter code) LQEEDAGEYGCM-amide
Sequence (three letter code)

H-Leu-Gln-Glu-Glu-Asp-Ala-Gly-Glu-Tyr-Gly-Cys-Met-NH2

Aliase LR12
Purity >95%
Storage -20°C
References

Derive et al (2013) Effects of a TREM-Like Transcript 1–Derived Peptide During Hypodynamic Septic Shock in Pigs. Shock 39(2) 176 PMID: 23324887

Derive et al (2014) Attenuation of Responses to Endotoxin by the Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor LR12 in Nonhuman Primate. Anesthesiology 120(4) 935 PMID: 24270127

Derive et al (2012) Soluble Trem-like Transcript-1 Regulates Leukocyte Activation and Controls Microbial Sepsis. J. Immunol. 188(11) 5585 PMID: 22551551

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Nangibotide, also referred as LR12, is an antagonist of triggering receptor expressed on myeloid cells (TREM)-1, and was derived from residues 94 to 105 of TREM-like transcript-1 (TLT-1).

TREM-1 plays a crucial role in the onset of sepsis by amplifying the host immune response. TLT-1– and TLT-1–derived peptides therefore exhibit anti-inflammatory properties by dampening TREM-1 signalling.  LR12 blocks TREM-1 by binding to the TREM-1 ligand and provides protective effects during sepsis such as inhibiting hyper-responsiveness, organ damage, and death, without causing deleterious effects. The protective effects of modulating TREM-1 signalling are also evident in other models of inflammation such as: pancreatitis; haemorrhagic shock; inflammatory bowel diseases and inflammatory arthritis

Nangibotide

Cat No.Pack SizePriceQty.
0.5mg£85.00
1mg£110.00
5mg£350.00
Bulk Quote